Educational information only. This site does not provide medical advice. Read full disclaimer
    PepTracker Pro
    Open the App
    Research-only content. This page is for educational purposes and does not constitute medical advice. Read full disclaimer →

    Mazdutide

    High Evidence

    The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide.

    AliasesIBI362+1 more
    EvidenceHigh Evidence
    Last Updated 2026-05-02
    Reading Time 2 min

    What It Is

    Mazdutide (IBI362/LY3305677) is a first-in-class dual glucagon (GCG)/GLP-1 receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. China's NMPA approved mazdutide for chronic weight management in adults with overweight or obesity, making it the first dual GCG/GLP-1 agonist approved anywhere globally. A separate NMPA approval was granted for glycemic control in adults with type 2 diabetes. In the GLORY-1 Phase 3 trial, the 6 mg dose produced 14.01% mean body weight reduction at 48 weeks versus 0.30% with placebo. The GLORY-2 Phase 3 trial of the 9 mg dose achieved up to 20.1% weight loss at 60 weeks in Chinese adults with obesity, with the NDA submission for the 9 mg dose expected in 2026. In the head-to-head DREAMS-3 Phase 3 trial, mazdutide demonstrated superiority over semaglutide in both glycemic control and weight loss in Chinese adults with type 2 diabetes. The GLORY-3 trial is evaluating mazdutide versus semaglutide in adults with obesity and metabolic-associated fatty liver disease (MAFLD), and GLORY-OSA is evaluating mazdutide in obesity with obstructive sleep apnea. Seven Phase 3 studies have been completed or are ongoing. Global regulatory filings outside China are expected.

    Also known as: IBI362, LY3305677

    Regulatory Status

    NMPA-Approved (China)

    Approved by China's NMPA for chronic weight management (6 mg) and glycemic control in T2D. 9 mg dose NDA pending. Not yet approved by FDA; global regulatory filings expected.

    Effective: 2025

    View FDA Source

    Proposed Mechanisms

    • GLP-1 receptor agonism reduces appetite and promotes satiety
    • Glucagon receptor activation increases energy expenditure and hepatic fat oxidation
    • Dual mechanism addresses both caloric intake and metabolic rate
    • Improves insulin sensitivity and glucose homeostasis in T2D
    • Reduces hepatic lipid accumulation through glucagon-mediated lipolysis

    Evidence Snapshot

    High Evidence
    Low
    Medium
    High
    Study Type Model Outcome Link
    Human (Phase 3) Chinese adults with obesity (NEJM) 14.01% weight loss at 48 weeks (6mg) vs 0.30% placebo Source
    Human (Phase 3) Chinese adults with T2D (Nature) HbA1c reduction of 2.15% (6mg) vs 0.14% placebo at 24 weeks Source
    Human (Phase 3) Head-to-head vs dulaglutide in T2D (Nature) Superior glycemic control and weight loss vs dulaglutide Source
    Human (Phase 3, GLORY-2) Mazdutide 9 mg in Chinese adults with obesity (60 weeks) Up to 20.1% weight loss at 60 weeks; met all primary and key secondary endpoints Source
    Human (Phase 3, DREAMS-3) Head-to-head vs semaglutide in Chinese adults with T2D Superiority over semaglutide in both glycemic control and weight loss Source
    Human (Phase 1) High-dose (up to 10mg) in adults with overweight/obesity Significant dose-dependent weight reduction Source

    Commonly Discussed Benefits

    Safety & Cautions

    • Approved in China only; not yet approved by FDA or EMA
    • Phase 3 data primarily in Chinese populations; global trials needed
    • Gastrointestinal side effects are the most common adverse events
    • Long-term cardiovascular outcome data not yet available
    • 9 mg high-dose NDA under review by NMPA

    Comparisons

    See how Mazdutide compares to related peptides:

    Calculator Tools

    Use our research tools to explore dosing and reconstitution data:

    Citations

    1. [1] Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight, NEJM 2025 PubMed
    2. [2] Mazdutide versus placebo in Chinese adults with T2D, Nature 2025 PubMed
    3. [3] Mazdutide versus dulaglutide in Chinese adults with T2D, Nature 2025 PubMed
    4. [4] GLORY-2: Mazdutide 9 mg achieves up to 20.1% weight loss — PRNewswire 2026 PubMed
    5. [5] DREAMS-3: Mazdutide shows superiority over semaglutide — Innovent 2026 PubMed
    6. [6] Innovent announces NMPA approval for T2D — PRNewswire 2026 PubMed

    Continue Your Research

    Track your research notes and set reminders in the companion app.

    Related Peptides

    Tirzepatide

    High Evidence

    A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.

    Semaglutide

    High Evidence

    A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

    Retatrutide

    High Evidence

    An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.

    Survodutide

    Medium Evidence

    A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.

    NA-931 (Bioglutide)

    Medium Evidence

    The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation.

    UBT251

    Medium Evidence

    A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space.